Evaluation of the effect of SGLT-2 inhibitors on atrial fibrillation recurrence in diabetic patients.

IF 2.5 3区医学 Q3 PHARMACOLOGY & PHARMACY

Expert Opinion on Pharmacotherapy Pub Date : 2025-07-03 DOI:10.1080/14656566.2025.2527189

Mücahit Yarar, Hasan Ari, Selma Ari, Ahmet Tütüncü, Mehmet Melek, Tahsin Bozat

{"title":"Evaluation of the effect of SGLT-2 inhibitors on atrial fibrillation recurrence in diabetic patients.","authors":"Mücahit Yarar, Hasan Ari, Selma Ari, Ahmet Tütüncü, Mehmet Melek, Tahsin Bozat","doi":"10.1080/14656566.2025.2527189","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to investigate the effect of SGLT-2 (sodium glucose cotransporter-2) inhibitors on AF (atrial fibrillation) recurrence in patients diagnosed with diabetes mellitus (DM) who underwent Direct Current Cardioversion (DCCV) in our clinic.Research design and methods: Consecutive DCCV was performed to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who didn't use SGLT-2 inhibitors). The two groups (SGLT-2 inhibitor user group and control group) were monitored for AF recurrence on the first day, then at one, three, and six months after CV.Results: During the six-month follow-up period, AF recurrence developed in 24 (40%) patients in SGLT-2 inhibitor group and in 35 (58.3%) of the control group, p = 0.04. In univariable analysis, AF duration, non-use of SGLT-2 inhibitor, left atrium diameter, TAPSE value and in multivariable analysis, AF duration OR: 4.98; 95%CI (2.39-10.38), p < 0,001 and non-use of SGLT-2 inhibitors OR: 0.35; 95%CI (0.13-0.90), p = 0.03 were found to be independent predictors for AF recurrence.Conclusion: AF recurrence ratio is significantly lower in patients using SGLT-2 inhibitors, in six-month follow-up period. AF duration and SGLT-2 inhibitor non-use were independent predictors, for AF recurrence in DM patients (NCT06951737).Clinical trial registration: www.clinicaltrials.gov identifier is: NCT06951737.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2025.2527189","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to investigate the effect of SGLT-2 (sodium glucose cotransporter-2) inhibitors on AF (atrial fibrillation) recurrence in patients diagnosed with diabetes mellitus (DM) who underwent Direct Current Cardioversion (DCCV) in our clinic.

Research design and methods: Consecutive DCCV was performed to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who didn't use SGLT-2 inhibitors). The two groups (SGLT-2 inhibitor user group and control group) were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Results: During the six-month follow-up period, AF recurrence developed in 24 (40%) patients in SGLT-2 inhibitor group and in 35 (58.3%) of the control group, p = 0.04. In univariable analysis, AF duration, non-use of SGLT-2 inhibitor, left atrium diameter, TAPSE value and in multivariable analysis, AF duration OR: 4.98; 95%CI (2.39-10.38), p < 0,001 and non-use of SGLT-2 inhibitors OR: 0.35; 95%CI (0.13-0.90), p = 0.03 were found to be independent predictors for AF recurrence.

Conclusion: AF recurrence ratio is significantly lower in patients using SGLT-2 inhibitors, in six-month follow-up period. AF duration and SGLT-2 inhibitor non-use were independent predictors, for AF recurrence in DM patients (NCT06951737).

Clinical trial registration: www.clinicaltrials.gov identifier is: NCT06951737.

查看原文本刊更多论文

SGLT-2抑制剂对糖尿病患者房颤复发的影响。

背景：本研究的目的是探讨SGLT-2（葡萄糖共转运蛋白2钠）抑制剂对临床诊断为糖尿病（DM）患者行直流心律转复（DCCV）后房颤（AF）复发的影响。研究设计和方法：连续进行DCCV，直到120例SR患者（60例使用SGLT-2抑制剂的DM患者和60例未使用SGLT-2抑制剂的DM患者）。患者分为SGLT-2抑制剂使用组和对照组。两组在第一天监测房颤复发，然后在CV后1、3和6个月监测房颤复发。结果：随访6个月，SGLT-2抑制剂组AF复发24例（40%），对照组35例（58.3%），p = 0.04。单变量分析中，房颤持续时间、SGLT-2抑制剂、左心房直径和TAPSE值是房颤复发的重要参数。在多变量分析中，AF持续时间OR: 4.98；95% CI (2.39 ~ 10.38), p = 0.03是房颤复发的独立预测因子。结论：在6个月的随访期内，使用SGLT-2抑制剂的患者房颤复发率明显降低。房颤持续时间和未使用SGLT-2抑制剂是DM患者房颤复发的独立预测因子（NCT06951737）。临床试验注册：www.clinicaltrials.gov标识符：NCT06951737。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Pharmacotherapy 医学-药学

CiteScore

5.60

自引率

3.10%

发文量

163

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.